Publications 2010

1 Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. V Soriano, A Mocroft, L Peters, J Rockstroh, F Antunes, N Kirkby, S de Wit, A d'Arminio Monforte, Robert Flisiak and J Lundgren on behalf of EuroSIDA
J Antimocrob Chemother. 2010 Jan 5. Epub ahead of print. PubMed PMID: 20051475; article

2 Relationship between current level of immunodeficiency and non-AIDS defining malignancies. J Reekie, C Kosa, F Engsig, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren, A Mocroft for the EuroSIDA study group.
Cancer. (in press)

3 Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years.The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Arch Intern Med 2010, 170:410-419.article

4 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, AN Phillips, B Ledergerber, JD Lundgren, for the EuroSIDA Study Group.
AIDS (in press).

5 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. The Antiretroviral Therapy Cohort Collaboration Study Group (ART-CC).
Clin Infect Dis. 2010 May 15;50(10):1387-96. abstract

6 High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin, for the DAD study group.
AIDS. 2010 Jan 28;24(3):427-35. article

7 Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Worm SW, Sabin S, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Fontas E, Weller I, Phillips a, Lundgren J.
J Infect Dis. 2010 Feb 1;201(3):318-30. PubMed PMID: 20039804 article

8 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
Clinical Infectious Diseases. 2010;51(5):000-000. article

9 Estimated average annual rate of change of CD4 counts in patients on combination antiretroviral therapy. A Mocroft, AN Phillips, B Ledergerber, C Smith, JR Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Antiviral Therapy 2010. 15:563-570. article

Updated: 28 Jul 2010